93 248

Cited 0 times in

Impact of neoadjuvant treatment on rectal gastrointestinal stromal tumors

Authors
 Chinock Cheong  ;  Jeonghyun Kang  ;  Byung Soh Min  ;  Nam Kyu Kim  ;  Joong Bae Ahn  ;  Kang Young Lee 
Citation
 PLOS ONE, Vol.17(9) : e0270887, 2022-09 
Journal Title
PLOS ONE
Issue Date
2022-09
MeSH
Antineoplastic Agents* / therapeutic use ; Gastrointestinal Stromal Tumors* / drug therapy ; Gastrointestinal Stromal Tumors* / surgery ; Humans ; Imatinib Mesylate / therapeutic use ; Margins of Excision ; Neoadjuvant Therapy ; Rectal Neoplasms* / drug therapy ; Rectal Neoplasms* / pathology ; Retrospective Studies
Abstract
Although gastrointestinal stromal tumors (GISTs) are rare disease and rectal GISTs is only 5% of total GISTs, they have the worst prognosis. Due to narrow pelvis, tumor rupture or positive resection margin are common in the management of rectal GISTs. The impact of neoadjuvant treatment on the clinical outcomes of rectal gastrointestinal stromal tumors (GISTs) remains unclear. Thus, we conducted a retrospective study to investigate the impact of neoadjuvant imatinib on rectal GIST. The cohort comprised 33 patients; of them, 10 and 23 belonged to the neoadjuvant (i.e., those who underwent neoadjuvant imatinib treatment) and the control group (i.e., those who underwent surgery without prior imatinib treatment), respectively. Neoadjuvant group was associated with more common levator ani muscle displacement (P = 0.002), and showed significantly larger radiologic tumor size (P = 0.036) than the control group. The mean tumor size was significantly decreased after imatinib treatment (6.8 cm to 4.7cm, P = 0.006). There was no significant difference in resection margin involvement (P >0.999), and sphincter preservation rates (P = 0.627) between the two groups. No difference was observed with respect to morbidities, hospital stay, local recurrence and disease-free survival. Neoadjuvant imatinib treated group had similar propensity with control group after treatment. We thought reduced tumor sized could enhance resectability and provide more chance to preserve sphincter for rectal GIST patients. Considering large tumor size and higher rate of sphincter invasion in the neoadjuvant group, imatinib treatment could be helpful as a conversion strategy to make huge and low-lying rectal GIST operable and achieve better surgical outcomes.
Files in This Item:
T202203921.pdf Download
DOI
10.1371/journal.pone.0270887
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Jeonghyun(강정현) ORCID logo https://orcid.org/0000-0001-7311-6053
Kim, Nam Kyu(김남규) ORCID logo https://orcid.org/0000-0003-0639-5632
Min, Byung Soh(민병소) ORCID logo https://orcid.org/0000-0003-0180-8565
Ahn, Joong Bae(안중배) ORCID logo https://orcid.org/0000-0001-6787-1503
Lee, Kang Young(이강영)
Cheong, Chin Ock(정진옥)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/192089
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links